Nina Kjellson

General Partner / West Coast

Since 2015

Nina Kjellson invests in biopharma and digital health companies that serve unmet therapeutic and access needs. As a leader of Canaan’s Women of Venture program, Nina is a vocal advocate for women entrepreneurs and investors. She serves as a mentor to Blueprint Health and Springboard Life Sciences and on the boards of Essential Access Health, the California Leadership Council for The Nature Conservancy and the Oliver Wyman Health Innovation Center. Nina is also a 2018 Aspen Institute Health Innovators Fellow. Previously, Nina was a General Partner at Interwest Partners. She holds a B.A. in human biology from Stanford University.

Nina in 5

Origins: Born in Scandinavia

Travel: Have a major case of wanderlust (with a passport to prove it)

Sport: Love being outdoors & deep in nature

Interests: A good book (or Ripple by the Grateful Dead) can turn any day around

Family: Nothing beats time spent with my family & friends



Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases

BioCentury: Biotech investors bracing for Inflation Reduction Act’s impacts

Fierce Biotech: Tyra Biosciences named to 2021 Fierce 15 List

Fierce Biotech: Tyra Biosciences banks $173M to bring cancer resistance programs into clinic

In Vivo: The talent crisis – How to improve recruitment and retain biopharma employees

In Vivo: Biotech’s double-edged sword – Extraordinary funding run contributes to talent crisis

Reconvening for a virtual Women Who Venture gathering

Forbes: Nearly 50% of venture-backed healthcare companies have no women on the board, new report shows

Endpoints News: Why do some targeted cancer therapies stop working? For Tyra, that's the $106M question

FierceBiotech: Tyra Biosciences banks $106M, adds to C-suite as it aims for the clinic in 2022

Vaccinating with speed and equity: A conversation with Dr. Rebecca Weintraub

Nina Kjellson: More than words. Extreme(ly) satisfying steps together towards greater health equity

C&EN: The year in pharma - IPO window remained wide open

BioCentury: Larger stakes, more newcos as Canaan moves to bump up biopharma investments with new $800M fund

Endpoints News: Canaan raises another $800M as it launches its next fund with an emphasis on biotech

The Best of WoVen: Stepping into the unknown

The Best of WoVen: The importance of community

The Best of WoVen: Balancing work and family

Endpoints News: Gilead lines up a $1.55B biotech buyout deal as CEO Dan O’Day invests in his latest cancer blockbuster dream

BioCentury: With equity-and-option deal for Tizona, Gilead places latest bet on cancer immunosuppression

FierceBiotech: Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead

The Best of WoVen: Combatting prejudice and inspiring change

The Best of WoVen: Self-care and how to look after body and mind

Endpoints News: Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D

Nina Kjellson: Biotechnology in the time of COVID-19

The Best of WoVen: Resilience and how to bounce back stronger

Timmerman Report: Finding a path in biotech VC - Nina Kjellson on The Long Run Podcast

Bio-IT World: Lessons from personalized medicine can supercharge coronavirus testing

Timmerman Report: Do's and don'ts of staying connected in a time of social distancing

San Francisco Business Times: "Say it" - Nina Kjellson, Amy DuRoss and Gail Maderis on the barriers to funding women's health issues

Timmerman Report: First buy, then invest - Novartis, Gilead join $35M bet on Vineti's software

CNBC: These start-ups are racing to help doctors detect cancer early with a simple blood test

WoVen Podcast: The woman who gets inside the heads of execs at Facebook, Google and more - A conversation with Glo Harris

Annual Women Who Venture Gathering 2020

Endpoints News: RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs

BioCentury: Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

FierceBiotech: Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise

STAT News: Amy DuRoss - To make advanced therapies, we need to industrialize personalization

WoVen Podcast: Democratizing healthcare with activist roots - A conversation with Amy DuRoss

Xconomy: With $9.5M, Intrepida Bio launches to target pancreatic cancer & more

Endpoints News: Neoantigen player PACT Pharma woos Tim Moore from Kite to run technical ops

WoVen Podcast: Working with grit (and a patient's perspective) in women’s health - A conversation with Gail Maderis

FierceBiotech: A personalized CAR-T to attack every solid tumor? PACT Pharma has a plan

WoVen Podcast: Blazing a trail (and building a family) as a pioneering VC - A conversation with Ginger More

MedCityNews: Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study

WoVen Podcast: Crafting success (and balance) in venture - A conversation with Wende Hutton

WoVen Podcast: Breaking ground (and battling bias) in brain surgery - A conversation with Dr. Odette Harris

Nina Kjellson: Introducing the WoVen Podcast, a series that celebrates remarkable women in healthcare, tech & business

BioCentury: Vineti is keeping cell therapies on track

Nina Kjellson: The roadmap for board diversity

Nina Kjellson: In case of emergency -- expert tips for weathering a crisis

Nina Kjellson: "Jumping together" to move the field of personalized cancer therapy

BioCentury: Why GV and Canaan backed PACT Pharma's hyperpersonalized cancer approach

Nina Kjellson: Practical tips from two male biotech CEOs who are leaning in

Nina Kjellson: When it comes to women in venture, a 30x return on each other

Nina Kjellson: A critical marriage for science and health tech

Bloomberg Tech: Canaan Partners see race for firms to hire more women

Endpoints News: When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?

CNBC: After a miserable 2017, VCs offer predictions on digital health IPOs for 2018

FiercePharma: 2017’s fiercest women in life sciences

CNBC: 11 women who prove that health tech investing isn’t a boys’ club

Bloomberg: America’s drinking problem is much worse this century

Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

BioTech Nation Podcast: Women in biotech venture capital

Cigna collaborates with Annum Health to introduce a digital health solution to help people reduce alcohol consumption

Nina Kjellson: Why I'm excited to help reinvent treatment for heavy drinking

Nina in 5

Origins: Born in Scandinavia

Travel: Have a major case of wanderlust (with a passport to prove it)

Sport: Love being outdoors & deep in nature

Interests: A good book (or Ripple by the Grateful Dead) can turn any day around

Family: Nothing beats time spent with my family & friends